Contents
pdf Download PDF
pdf Download XML
233 Views
1 Downloads
Share this article
Research Article | Volume:24 Issue 1 (Jan-Dec, 2019) | Pages 1 - 2
Recovery of Organophosphorus Poisoning and Progression to Intermediate Syndrome- A Case Report
 ,
 ,
 ,
 ,
 ,
Under a Creative Commons license
Open Access
Received
March 10, 2019
Revised
June 20, 2019
Accepted
Sept. 30, 2019
Published
Oct. 25, 2019
Abstract

Background: Organophosphorus (OP) pesticide poisoning is a major public health concern across Indian population. Its ingestion is associated with high morbidity and mortality. Early recognition and prompt management is important for saving patient’s life. Organophosphorus poisoning leads to three main syndromes: a) acute cholinergic syndrome b) intermediate syndrome c) OP induced delayed polyneuropathy.

Case Report: A 30-year-old female patient presented in emergency after consumption of organophosphorus pesticide. After proper resuscitation she was given atropine and pralidoxime and intubated and shifted to ICU. She was extubated after complete recovery but showed symptoms of muscle weakness and respiratory distress after two days pointing towards intermediate syndrome, an uncommon subacute complication of organophosphorus poisoning. The symptoms resolved with the use of glycopyrrolate and the patient eventually made a complete recovery.

Conclusion: Intermediate syndrome is characterized by the onset of weakness of neck flexors, proximal limb muscles and respiratory muscles within one to four days after organophosphorus poisoning. Recognition of this syndrome is important as it affects the respiratory system which may require ventilatory support.

Keywords
Recommended Articles
Depression and distressed (Type D) personality: What is their impact on cardiovascular outcomes?
Research Article
Trans- Masseteric Antero-Parotid Approach for Open Reduction Internal Fixation of Mandibular Sub Condylar Fractures
...
Published: 25/10/2019
In sport is it all mind over matter
Research Article
Interindividual Variability in response to aspirin and P2Y12 blockers in patients at high cardiovascular risk-the state of the evidence
© Copyright Dialogues in Cardiovascular Medicine